Article

Variation in Medication Adherence in Heart Failure

JAMA Internal Medicine (Impact Factor: 13.25). 02/2013; 173(6):1-2. DOI: 10.1001/jamainternmed.2013.2509
Source: PubMed
0 Followers
 · 
82 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Heart failure (HF) accounts for over 1 million primary hospitalizations in the USA each year and carries a tremendous burden on costs and patient outcomes. The clinical syndrome of HF is not a single disease, but represents the complex interplay between various cardiac and non-cardiac processes, each of which need to be individually addressed. This review provides an updated, contemporary roadmap for inpatient worsening chronic HF management with a focus on identifying and addressing initiating mechanisms, amplifying factors, and cardiac structural abnormalities. Inpatient risk stratification should guide patient education, team structuring, disposition, and post-discharge monitoring.
    Journal of Cardiology 09/2014; 65(1). DOI:10.1016/j.jjcc.2014.08.011 · 2.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Few studies have investigated regional variation in medication-taking behaviour. The purpose of this study was to investigate whether there are regional differences in non-persistence and non-adherence to oral anti-hyperglycaemic agents in patients initiating therapy and examine if any association exists between different types of comorbidity in terms of medication-taking behaviour. Methods The Irish Health Services Executive (HSE) pharmacy claims database was used to identify new users of metformin or sulphonylureas, aged ≥25 years, initiating therapy between June 2009 and December 2010. Non-persistence and non-adherence were examined up to 12 months post-initiation. Comorbidity was assessed using modified RxRisk and RxRisk-V indices, and classified as either concordant and/or discordant with diabetes. Adjusted hazard ratios (HRs) and 95 % confidence intervals (95 % CIs) for non-persistence were determined in relation to both HSE region and comorbidity type using Cox proportional hazards model, adjusting for age, sex and initial OAH prescribed. Logistic regression analysis, adjusting for these covariates, was used to determine the adjusted odds ratios (ORs) and 95 % CIs for non-adherence for both HSE region and comorbidity type. Results Results showed little overall difference between regions. The largest reduction for both non-persistence (HR 0.86, 95 % CI 0.80, 0.94) and non-adherence (OR 0.83, 95 % CI 0.74, 0.93) was observed in the south. Any comorbidity was associated with a reduced risk of non-persistence and non-adherence. Conclusions Interventions to optimise medication-taking in patients with T2DM should be implemented nationally to improve the overall level of adherence and persistence, especially in patients with no comorbidity.
    Irish Journal of Medical Science 05/2014; 184(2). DOI:10.1007/s11845-014-1132-1 · 0.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: It remains unclear whether dabigatran etexilate mesylate is associated with higher risk of bleeding than warfarin sodium in real-world clinical practice.
    JAMA Internal Medicine 11/2014; 175(1). DOI:10.1001/jamainternmed.2014.5398 · 13.25 Impact Factor